Edwards Lifesciences Corporation (EW) Insider Trading Activity

NYSE$73.98
Market Cap
$43.4B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
565 of 871
Rank in Industry
67 of 109

EW Insider Trading Activity

EW Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$15,297,212
38
100

Related Transactions

Markowitz WayneGM & SVP, Surgical
0
$0
2
$62,837
$-62,837
Chopra DaveenCVP, TMTT
0
$0
3
$328,273
$-328,273
Lippis Daniel J.CVP, JAPAC
0
$0
8
$426,523
$-426,523
STONE HEISZ LESLIEdirector
0
$0
1
$435,371
$-435,371
LORANGER STEVEN Rdirector
0
$0
1
$438,576
$-438,576
Zovighian Bernard JCEO
0
$0
4
$2.19M
$-2.19M
Wood Larry LGlobal President TAVR & Surg
0
$0
2
$2.32M
$-2.32M
BOBO DONALD E JRCVP,Strategy/Corp Development
0
$0
11
$4.51M
$-4.51M
Ullem Scott B.CVP, Chief Financial Officer
0
$0
6
$4.58M
$-4.58M

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Insider Activity of Edwards Lifesciences Corporation

Over the last 12 months, insiders at Edwards Lifesciences Corporation have bought $0 and sold $15.3M worth of Edwards Lifesciences Corporation stock.

On average, over the past 5 years, insiders at Edwards Lifesciences Corporation have bought $109,049 and sold $69.55M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 580 shares for transaction amount of $49,753 was made by Zovighian Bernard J (CEO) on 2024‑05‑06.

List of Insider Buy and Sell Transactions, Edwards Lifesciences Corporation

2025-06-16SaleWood Larry LGlobal President TAVR & Surg
8,950
0.0015%
$75.23
$673,268
-1.42%
2025-06-03SaleZovighian Bernard JCEO
967
0.0002%
$77.32
$74,772
-2.26%
2025-06-02SaleBOBO DONALD E JRCVP,Strategy/Corp Development
2,570
0.0004%
$77.40
$198,911
-2.19%
2025-05-30SaleZovighian Bernard JCEO
16,099
0.0027%
$77.21
$1.24M
-2.31%
2025-05-22SaleChopra DaveenCVP, TMTT
1,500
0.0003%
$75.08
$112,613
+1.70%
2025-05-09SaleUllem Scott B.CVP, Chief Financial Officer
11,250
0.0019%
$74.40
$837,035
+2.88%
2025-05-09SaleLippis Daniel J.CVP, JAPAC
330
<0.0001%
$74.42
$24,560
+2.88%
2025-05-07SaleMarkowitz WayneGM & SVP, Surgical
268
<0.0001%
$75.08
$20,121
+2.04%
2025-05-05SaleZovighian Bernard JCEO
5,980
0.001%
$74.91
$447,977
+1.11%
2025-04-14SaleBOBO DONALD E JRCVP,Strategy/Corp Development
9,500
0.0016%
$69.81
$663,196
+8.34%
2025-04-08SaleLippis Daniel J.CVP, JAPAC
300
<0.0001%
$70.61
$21,183
+12.70%
2025-03-26SaleUllem Scott B.CVP, Chief Financial Officer
11,250
0.0019%
$70.87
$797,267
+5.73%
2025-03-13SaleBOBO DONALD E JRCVP,Strategy/Corp Development
9,500
0.0016%
$67.96
$645,624
+10.04%
2025-03-10SaleZovighian Bernard JCEO
6,164
0.0011%
$69.51
$428,448
+8.53%
2025-03-10SaleLippis Daniel J.CVP, JAPAC
400
<0.0001%
$69.48
$27,792
+8.53%
2025-02-28SaleUllem Scott B.CVP, Chief Financial Officer
11,250
0.0019%
$70.78
$796,327
+3.15%
2025-02-14SaleLORANGER STEVEN Rdirector
5,739
0.001%
$76.42
$438,576
-3.79%
2025-02-13SaleBOBO DONALD E JRCVP,Strategy/Corp Development
6,500
0.0011%
$75.75
$492,363
-3.27%
2025-02-13SaleUllem Scott B.CVP, Chief Financial Officer
11,250
0.0019%
$75.76
$852,272
-3.27%
2025-02-13SaleSTONE HEISZ LESLIEdirector
5,739
0.001%
$75.86
$435,371
-3.27%
Total: 1137
*Gray background shows transactions not older than one year

Insider Historical Profitability

17.7%
Wood Larry LGlobal President TAVR & Surg
206900
0.0353%
$15.31M0101
LORANGER STEVEN Rdirector
60372
0.0103%
$4.47M11
<0.0001%
BOBO DONALD E JRCVP,Strategy/Corp Development
50356
0.0086%
$3.73M0150
Ullem Scott B.CVP, Chief Financial Officer
41098
0.007%
$3.04M039
Chopra DaveenCVP, TMTT
33496
0.0057%
$2.48M018
STONE HEISZ LESLIEdirector
30035
0.0051%
$2.22M05
Lippis Daniel J.CVP, JAPAC
26616
0.0045%
$1.97M011
Markowitz WayneGM & SVP, Surgical
9299
0.0016%
$687,954.1902
Zovighian Bernard JCEO
8597
0.0015%
$635,972.85110
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
173849
0.0296%
$12.86M024
Verguet Patrick BCVP, Europe
129137
0.022%
$9.55M091
KEHL JOHN H JRCVP, Strategy & Corp Dev
102839
0.0175%
$7.61M027
WANG HUIMINCVP, Japan & Intercontinental
99381
0.0169%
$7.35M0156
Cardis John Tdirector
91458
0.0156%
$6.77M05
BOWLIN MICHAEL Rdirector
81751
0.0139%
$6.05M010
GALLAHUE KIERANdirector
67219
0.0115%
$4.97M22
+27.32%
VALERIANI NICHOLAS Jdirector
63811
0.0109%
$4.72M11
<0.0001%
GARREN BRUCE PCVP, Public Affairs/Special Co
62748
0.0107%
$4.64M017
PYOTT DAVID E Idirector
48429
0.0083%
$3.58M16
+10.01%
MCNEIL BARBARA Jdirector
46454
0.0079%
$3.44M15
+33.89%
Abate Thomas MCVP, CFO
44393
0.0076%
$3.28M023
Szyman Catherine M.CVP, Critical Care
34814
0.0059%
$2.58M156
+31.99%
Solomon Carlyn DCVP, Critical Care & Vascular
31154
0.0053%
$2.3M018
INGRAM ROBERT ALEXANDERdirector
30541
0.0052%
$2.26M05
BESSLER ANITACVP
29410
0.005%
$2.18M07
NEAL PHILIP Mdirector
27333
0.0047%
$2.02M01
Marsh Martha H.
26777
0.0046%
$1.98M01
LOUCKS VERNON R JRdirector
17106
0.0029%
$1.27M02
FOSTER STUART LCVP, Critical Care / Vascular
17300
0.0029%
$1.28M08
Nevinny Corinne HCVP & Pres., Global Ops
16687
0.0028%
$1.23M013
SELLERS ROBERT W.A.SVP, Corporate Controller
13087
0.0022%
$968,189.86018
Redmond Paul CCVP, Global Operations
12534
0.0021%
$927,265.32014
Martin John AlexanderCVP, North America
11300
0.0019%
$835,974.0001
VON SCHACK WESLEY Wdirector
8000
0.0014%
$591,840.0036
+20.17%
MUSSALLEM MICHAEL Adirector
4486
0.0008%
$331,860.960239
LINK WILLIAM J PHDdirector
4722
0.0008%
$349,333.5605
McCauley Christine ZCVP, Human Resources
4234
0.0007%
$313,231.3201
WOODGRIFT RANDEL WILLIAMCorp VP, Manufacturing Ops
3349
0.0006%
$247,759.0204
REINDL ROBERT CCVP, H.R. and Communications
1124
0.0002%
$83,153.52023
*Gray background shows insiders who have made transactions during last year

EW Institutional Investors: Active Positions

Increased Positions510+34.6%45M+8.85%
Decreased Positions634-43.01%39M-7.66%
New Positions117New7MNew
Sold Out Positions128Sold Out8MSold Out
Total Postitions1,350-8.41%514M+1.2%

EW Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$5.23M11.8%69.13M+7M+10.44%2024-12-31
Blackrock, Inc.$4.14M9.34%54.71M+191,273+0.35%2025-03-31
Wellington Management Group Llp$2.51M5.67%33.21M+2M+5.32%2024-12-31
State Street Corp$1.95M4.4%25.81M-457,011-1.74%2024-12-31
Bank Of New York Mellon Corp$1.34M3.01%17.66M-468,983-2.59%2025-03-31
Jpmorgan Chase & Co$1.12M2.53%14.85M+6M+75.43%2024-12-31
Geode Capital Management, Llc$1.03M2.33%13.65M+126,194+0.93%2024-12-31
Jennison Associates Llc$763,008.001.72%10.09M+3M+34.31%2025-03-31
Fisher Asset Management, Llc$739,500.001.67%9.78M+696,965+7.68%2024-12-31
Citadel Advisors Llc$712,477.001.61%9.42M+7M+372.91%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.